Biogen (NASDAQ:BIIB – Get Free Report) and Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.
Valuation & Earnings
This table compares Biogen and Whitehawk Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biogen | $9.89 billion | 3.37 | $1.29 billion | $5.65 | 39.95 |
| Whitehawk Therapeutics | $7.14 million | 28.11 | -$20.60 million | ($1.12) | -3.14 |
Risk & Volatility
Biogen has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Biogen and Whitehawk Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biogen | 1 | 13 | 17 | 1 | 2.56 |
| Whitehawk Therapeutics | 1 | 0 | 7 | 0 | 2.75 |
Biogen currently has a consensus target price of $231.07, suggesting a potential upside of 2.38%. Whitehawk Therapeutics has a consensus target price of $8.33, suggesting a potential upside of 136.74%. Given Whitehawk Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Biogen.
Profitability
This table compares Biogen and Whitehawk Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biogen | 8.32% | 11.18% | 6.88% |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
Insider & Institutional Ownership
87.9% of Biogen shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Biogen beats Whitehawk Therapeutics on 10 of the 15 factors compared between the two stocks.
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin’s lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer’s disease and dementia, neuromuscular disorders, Parkinson’s disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
